Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AB001 (ARTBIO)
- Development stage
- Unknown
- Lead developer
- ARTBIO
- Modality
- Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
AB001 is an alpha radioligand therapy (ART) developed by ARTBIO Inc. for the treatment of metastatic castration-resistant prostate cancer (mCRPC). The drug consists of a small molecule ligand targeting prostate-specific membrane antigen (PSMA) radiolabeled with Lead-212 (Pb-212). AB001 delivers high-energy alpha particles directly to PSMA-expressing cancer cells, causing lethal double-stranded DNA breaks while minimizing damage to surrounding healthy tissue. It is manufactured using the proprietary AlphaDirect technology, which enables distributed production of the Pb-212 isotope. As of early 2026, the drug was in Phase 1 clinical development (ARTISAN trial), though a voluntary clinical hold was implemented in April 2026.
- Other names
- Pb-212 PSMA targeted alpha radioligand therapyPb212 PSMA targeted alpha radioligand therapyPb 212 PSMA targeted alpha radioligand therapy212Pb-AB001
02
Targets
PSMA (Prostate-specific membrane antigen)
Beyond the preview
Go deeper on AB001 (ARTBIO).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AB001 (ARTBIO).